Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment
INCHEON, South Korea, June 14 (Bernama-BUSINESS WIRE) — Celltrion Group today announced top-line efficacy and safety data from the global Phase…